ArticleJACC. CardioOncology2026
Hemoglobin Decline After Oral Anticoagulation Initiation and Subsequent Cancer Detection in Patients With Atrial Fibrillation.
Article in JACC. CardioOncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hemoglobin Decline and Occult Cancer After OAC Initiation: "No Smoke Without Fire?"JACC. CardioOncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies evaluating cancer risk during oral anticoagulation (OAC) have focused on overt bleeding events, whereas the significance of hemoglobin (Hb) decline in the absence of clinically overt bleeding events after OAC initiation has not been evaluated.
objectivesThe purpose of this study was to evaluate the association between Hb decline after OAC initiation in the absence of clinically overt bleeding events and subsequent cancer risk in patients with atrial fibrillation (AF).
methodsUsing the Korean National Health Insurance Service database linked to serial health examinations, 6,789 patients with AF were identified who underwent 2 examinations within 1 year before and after OAC initiation. Patients with prior cancer, end-stage renal disease, overt bleeding, or early OAC discontinuation were excluded. Patients were classified by Hb change (Hb decrease ≥2 g/dL vs no significant decrease). The primary outcome was incident cancer; secondary outcomes included site-specific cancers, all-cause mortality, thromboembolic events, and bleeding outcomes.
resultsDuring a median follow-up period of 10.6 months, patients with Hb decreases ≥2 g/dL had a higher incidence of overall cancer than those without (6.7 vs 4.3 per 100 person-years; adjusted HR: 1.42; 95% CI: 1.10-1.97). The association was particularly evident for gastrointestinal cancers (adjusted HR: 1.78; 95% CI: 1.12-2.83). Cancer risk associated with Hb declines was greater in older patients, those with chronic kidney disease, and those receiving antiplatelet therapy (P for interaction < 0.05). Hb decline was also associated with higher all-cause mortality and major bleeding, with no differences in stroke.
conclusionsIn patients with AF initiating OAC, Hb decline ≥2 g/dL in the absence of clinically overt bleeding events is associated with increased cancer risk, particularly gastrointestinal malignancy, and higher mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.